Brands: Emzole 100 mg / Meben–500 500 mg
Composition: Mebendazole USP 100 mg or 500 mg per uncoated tablet
Usage: Treatment of susceptible intestinal worm infections
Category: Anthelmintic Drugs
Therapeutic category: Anthelmintic / Antiparasitic
SKU: Mebendazole Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Mebendazole Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Mebendazole Tablets (100 mg / 500 mg)
Manufacturer: Healthy Life Pharma Pvt. Ltd. (certification subject to verification)
Exporter: Healthy Inc (export credentials subject to verification)
Mebendazole is an anthelmintic medicine used to treat certain intestinal worm infections, including pinworm, roundworm, whipworm and hookworm. Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter in the supplied product information. Confirm manufacturing and export credentials before publication.
The supplied products are Emzole 100 mg and Meben–500 500 mg, both described as uncoated tablets. Chewable or flavored versions should not be claimed without separate approved product information.
| Product name | Mebendazole Tablets |
|---|---|
| Brands | Emzole (100 mg); Meben–500 (500 mg) |
| Composition | Mebendazole USP 100 mg or 500 mg per tablet |
| Dosage form | Uncoated tablets (as supplied) |
| Therapeutic class | Benzimidazole anthelmintic / antiparasitic |
| CAS number | 31431-39-7 |
| Standard | USP (as supplied) |
| Packaging / shelf life | Confirm against approved pack and stability data |
For mebendazole, appropriate crystal-form control, particle-size management and blend uniformity may be relevant to product development. Polymorph selection, X-ray diffraction testing, micronization and particular compression methods are formulation-specific and must be confirmed from actual manufacturing records.
Any claims about chewable technology or specialized school-program packaging require product-specific verification.
Finished-product quality control should follow the applicable approved pharmacopoeial monograph and registration specifications, including identification, assay, content uniformity, dissolution where required, impurities and stability. Numerical acceptance criteria should be taken from the applicable validated method, not assumed.
Mebendazole interferes with parasite microtubule function by binding to beta-tubulin, impairing glucose uptake and other essential processes. It is used for susceptible intestinal helminths, including Enterobius vermicularis (pinworm), Ascaris lumbricoides (roundworm), Trichuris trichiura (whipworm) and certain hookworms.
It is an anthelmintic, not a general-purpose treatment for all protozoal infections. Selection depends on the organism, patient and local guidelines.
Registration dossiers, certificates of pharmaceutical product, certificates of analysis, manufacturing licenses, export authorizations and packaging options may be discussed with the supplier. Availability, regulatory approval, WHO-GMP status, and export documentation must be independently verified for the intended market.
Q: What strengths are listed?
A: Mebendazole USP 100 mg (Emzole) and 500 mg (Meben–500).
Q: Are these chewable tablets?
A: The supplied labels describe uncoated tablets; do not assume chewable use without the approved label.
Q: Is fasting necessary?
A: Fasting and laxatives are generally not needed for standard intestinal-worm treatment; follow the specific product label.
Q: Is it safe in pregnancy?
A: Use in pregnancy requires professional assessment, particularly during the first trimester.
The treatment schedule depends on the parasite, patient age and formulation. For example, pinworm regimens and treatment for roundworm, whipworm or hookworm differ, and repeat treatment may sometimes be necessary. Do not interchange 100 mg and 500 mg regimens without a clinician’s advice. Follow the locally approved prescribing information. Administration instructions for chewable products must not be applied automatically to these uncoated tablets.
Possible adverse effects include abdominal pain, diarrhea, nausea and rash. Rare but serious reactions can include severe skin reactions, blood-cell abnormalities and liver-related effects. Concurrent metronidazole use has been associated with serious skin reactions and should generally be avoided. Consult a healthcare professional for infants, pregnancy, liver disease, or persistent symptoms. Seek urgent care for severe rash or swelling.
Keep in the original packaging, protected from excessive moisture and out of reach of children. Follow the temperature and storage conditions printed on the approved product label; do not assume a 36-month shelf life without stability data.